CAR T-cell therapy in aggressive lymphomas-identifying prognostic and predictive markers

Alberto Mussetti1, Nicole Fabbri2, Anna Sureda1,3

  • 1Department of Hematology, Catalan Institute of Oncology, Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

Summary

Identifying prognostic factors before, during, and after anti-CD19 CAR T-cell therapy is key for improving outcomes in relapsed or refractory large B-cell lymphomas. Personalized treatment strategies are essential for patients undergoing this advanced therapy.

Related Concept Videos